Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses

E-ISSN： 2212-5299|4|5|587-596

ISSN： 1568-007X

Source： Current Drug Targets-CNS & Neurological Disorders, Vol.4, Iss.5, 2005-10, pp. : 587-596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nearly 200 X-Ray Crystal Structures of Transthyretin: What Do They Tell Us About This Protein and the Design of Drugs for TTR Amyloidoses?

Current Medicinal Chemistry, Vol. 19, Iss. 15, 2012-04 ,pp. : 2324-2342

Bentham Science Publishers

Access to resources Recommend Favorite

Methods to Evaluate the Inhibition of TTR Fibrillogenesis Induced by Small Ligands

Current Medicinal Chemistry, Vol. 19, Iss. 15, 2012-04 ,pp. : 2343-2355

Bentham Science Publishers

Access to resources Recommend Favorite

Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses

Current Pharmaceutical Design, Vol. 14, Iss. 30, 2008-10 ,pp. : 3219-3230

Bentham Science Publishers

Access to resources Recommend Favorite

TTR Fibril Formation Inhibitors: Is there a SAR?

Current Medicinal Chemistry, Vol. 19, Iss. 15, 2012-04 ,pp. : 2356-2379

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule and protein-based neurotrophic ligands: agonists and antagonists as therapeutic agents

By Saragovi H.U. Burgess K.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 737-751

Informa Healthcare

Access to resources Recommend Favorite